CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Appreciate the spectrum and incidence of HER2 alterations in non-small cell lung cancer (NSCLC), and evaluate the antitumor activity and safety of HER2-directed antibody-drug conjugates (ADCs) in patients with NSCLC and HER2 mutations or HER2 overexpression.
  • Describe how HER3 may mediate resistance to EGFR tyrosine kinase inhibitors, and discern how ADCs targeting HER3 may be beneficial for patients with progressive disease with EGFR mutations.
  • Appreciate the incidence of TROP2 overexpression in patients with NSCLC, and determine its potential utility as a biomarker of response to investigational ADCs for metastatic NSCLC.
  • Recognize the rationale for developing therapeutic agents for other novel targets such as CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) and c-MET for NSCLC, and appraise available efficacy data with these agents.
  • Discern the side effects and toxicities associated with ADCs under investigation for metastatic NSCLC.
  • Recall ongoing trials evaluating the potential role of novel ADCs for metastatic NSCLC, and counsel appropriate patients regarding enrollment.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Alexander I Spira, MD, PhD
  CEO and Clinical Director, NEXT Virginia
  Director, Virginia Cancer Specialists Research Program
  Fairfax, Virginia
  
  Consulting/Advisory Role: Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Gritstone bio, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Novartis, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, ADC Therapeutics, AI Therapeutics, Alkermes, Amgen Inc, Arch Therapeutics Inc, Astellas, Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Cardiff Oncology, CytomX Therapeutics, Daiichi Sankyo Inc, Gritstone bio, Ignyta Inc, Incyte Corporation, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lumos Pharma, MacroGenics Inc, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Novartis, Plexxikon Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines, Roche Laboratories Inc, Rubius Therapeutics, Synthekine Inc, Takeda Pharmaceuticals USA Inc; Honoraria: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, CytomX Therapeutics, Janssen Biotech Inc, Merck, Novartis, Takeda Pharmaceuticals USA Inc; Stock Options/Ownership: Lilly.
  
  Helena Yu, MD
  Medical Oncologist
  Associate Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, C4 Therapeutics, Cullinan Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc; Research Funding to My Institution: AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo Inc, Erasca, Janssen Biotech Inc, Novartis, Pfizer Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.
  
  Release date: December 2022
  Expiration date: December 2023